ArticleNature communications2026
Amine-linked heteroporous covalent organic framework for synergistic anti-infective therapy of post-traumatic osteomyelitis.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
The treatment of post-traumatic osteomyelitis (PTO) is impeded by bacterial biofilms and disruption of drug delivery systems in acidic lesions. Here, we develop an acid-resistant amine-linked heteroporous covalent organic framework (ARCOF) using a reductive amination strategy. This approach overcomes the insufficient chemical stability and drug delivery capacity of conventional COFs arising from the trade-off between high bond strength and crystalline reversibility. The pre-designed hetero-environmental channels of ARCOF enable synergistic loading of vancomycin and the anti-biofilm agent felodipine. When combined with calcium phosphate cement, both drugs exhibit sustained release over 240 h under inflammatory conditions. The therapeutic efficacy is evaluated in a rat PTO model, where the co-delivery system significantly enhances antibacterial efficacy by disrupting biofilm integrity and concurrently modulates the local inflammatory microenvironment to support bone tissue recovery. This strategy provides an integrated local delivery approach to overcome pharmacokinetic barriers and biofilm resistance in osteomyelitis treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.